What cardiovascular and kidney benefits, harms, and uncertainties are reported for GLP-1 receptor agonists in adults with type 2 diabetes?
A meta-analysis of eight placebo-controlled cardiovascular outcome trials involving 60,080 participants found that GLP-1 receptor agonists reduced major adverse cardiovascular events (MACE) by 14% (HR 0.86, 95% CI 0.80-0.93). It also reported relative reductions in all-cause mortality, heart-failure admission, and a composite kidney outcome. [1]
In LEADER, liraglutide reduced the primary MACE outcome from 14.9% to 13.0% over a median 3.8 years (HR 0.87, 95% CI 0.78-0.97), with lower cardiovascular and all-cause mortality. Gastrointestinal events were the most common reason for discontinuation. [2]
Limitations
- Most cardiovascular outcome trials enrolled people with established cardiovascular disease or elevated risk; absolute benefit is likely smaller in lower-risk populations.
- Pooled relative effects do not replace agent-specific evidence, baseline-risk assessment, or absolute event rates.
- Gastrointestinal intolerance is common, and the retinopathy signal in SUSTAIN-6 requires clinical context rather than simple class-wide extrapolation.
- The landmark trials were largely industry funded and generally compared treatment with placebo on top of standard care.